Robbins LLP Reminds Telix Pharmaceuticals Ltd. Stockholders About the January 9, 2026 Lead Plaintiff Deadline – Contact Us Today for Information About the TLX Class Action

Group 1 - The core focus of Telix Pharmaceuticals Ltd. is on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [1] - A class action has been filed on behalf of all investors who purchased or acquired Telix securities during the class period from February 21, 2025, to August 28, 2025 [1]